A new technology for the synthesis of anti-cancer antibodies
The major drawback of cancer treatments is their non-selectivity, which leads to significant side effects. Harnessing the immune system to fight cancer has emerged as a promising therapeutic approach. The EU-funded BispecificsThatClick project is focussing on the development of bispecific antibodies that target two antigens, one on cancer cells and the other on immune cells, leading to the efficient killing of the former. Scientists have developed a novel methodology to speed up and improve the efficiency of bispecific antibody production. The generated library of antibodies will be subjected to extensive analysis to determine their mode of action and their anti-tumour efficacy.